<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 22 Sep 2026 08:50:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study</title>
   <link>http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</link>
   <description>
&lt;p&gt;
&lt;b&gt;Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations&lt;/b&gt;

&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)--
The More Life Company Corp. (the “&lt;b&gt;Company&lt;/b&gt;” or &lt;b&gt;“MLCO”&lt;/b&gt;), (CSE: MLCO) (OTC: TMLCF), is pleased to announce results from an exploratory eight-participant human pharmacokinetic study conducted with third-party medical personnel to evaluate United States Pharmacopeia (“USP”) grade testosterone formulated using the Company’s patented Quicksome™ sublingual delivery technology.

&lt;/p&gt;&lt;p&gt;
The study showed rapid systemic appearance of USP testosterone following Quicksome administration, with substantial increases in measured serum testosterone observed within minutes of dosing. Peak serum testosterone concentrations were generally observed within</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</guid>
   <pubDate>Tue, 22 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study</title>
   <link>http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</link>
   <description>
&lt;p&gt;
&lt;b&gt;Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations&lt;/b&gt;

&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)--
The More Life Company Corp. (the “&lt;b&gt;Company&lt;/b&gt;” or &lt;b&gt;“MLCO”&lt;/b&gt;), (CSE: MLCO) (OTC: TMLCF), is pleased to announce results from an exploratory eight-participant human pharmacokinetic study conducted with third-party medical personnel to evaluate United States Pharmacopeia (“USP”) grade testosterone formulated using the Company’s patented Quicksome™ sublingual delivery technology.

&lt;/p&gt;&lt;p&gt;
The study showed rapid systemic appearance of USP testosterone following Quicksome administration, with substantial increases in measured serum testosterone observed within minutes of dosing. Peak serum testosterone concentrations were generally observed within</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</guid>
   <pubDate>Tue, 22 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study</title>
   <link>http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</link>
   <description>
&lt;p&gt;
&lt;b&gt;Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations&lt;/b&gt;

&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)--
The More Life Company Corp. (the “&lt;b&gt;Company&lt;/b&gt;” or &lt;b&gt;“MLCO”&lt;/b&gt;), (CSE: MLCO) (OTC: TMLCF), is pleased to announce results from an exploratory eight-participant human pharmacokinetic study conducted with third-party medical personnel to evaluate United States Pharmacopeia (“USP”) grade testosterone formulated using the Company’s patented Quicksome™ sublingual delivery technology.

&lt;/p&gt;&lt;p&gt;
The study showed rapid systemic appearance of USP testosterone following Quicksome administration, with substantial increases in measured serum testosterone observed within minutes of dosing. Peak serum testosterone concentrations were generally observed within</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</guid>
   <pubDate>Tue, 22 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Rapid Systemic Delivery of USP Testosterone in Exploratory Quicksome™ Study</title>
   <link>http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</link>
   <description>
&lt;p&gt;
&lt;b&gt;Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations&lt;/b&gt;

&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)--
The More Life Company Corp. (the “&lt;b&gt;Company&lt;/b&gt;” or &lt;b&gt;“MLCO”&lt;/b&gt;), (CSE: MLCO) (OTC: TMLCF), is pleased to announce results from an exploratory eight-participant human pharmacokinetic study conducted with third-party medical personnel to evaluate United States Pharmacopeia (“USP”) grade testosterone formulated using the Company’s patented Quicksome™ sublingual delivery technology.

&lt;/p&gt;&lt;p&gt;
The study showed rapid systemic appearance of USP testosterone following Quicksome administration, with substantial increases in measured serum testosterone observed within minutes of dosing. Peak serum testosterone concentrations were generally observed within</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Rapid+Systemic+Delivery+of+USP+Testosterone+in+Exploratory+Quicksome%E2%84%A2+Study/27088368.html</guid>
   <pubDate>Tue, 22 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Positive Third-Party Agrarius Potato Trial Results in Brazil</title>
   <link>http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</link>
   <description>
&lt;p&gt;&lt;b&gt;Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)-- The More Life Company Corp. (the “Company” or “TMLC”) (CSE: MLCO) (OTCID: TMLCF) is pleased to report positive results from an independently conducted field trial evaluating the Company’s licensed Agrarius™ agricultural plant signaling technology in potato crops in Brazil.&lt;/p&gt;&lt;p&gt;The leading Agrarius application programs recorded numerical yield increases of up to 32.5% in special-grade potatoes and up to 27.6% in total potato yield compared with the control.&lt;/p&gt;&lt;p&gt;The study</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</guid>
   <pubDate>Tue, 15 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Positive Third-Party Agrarius Potato Trial Results in Brazil</title>
   <link>http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</link>
   <description>
&lt;p&gt;&lt;b&gt;Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)-- The More Life Company Corp. (the “Company” or “TMLC”) (CSE: MLCO) (OTCID: TMLCF) is pleased to report positive results from an independently conducted field trial evaluating the Company’s licensed Agrarius™ agricultural plant signaling technology in potato crops in Brazil.&lt;/p&gt;&lt;p&gt;The leading Agrarius application programs recorded numerical yield increases of up to 32.5% in special-grade potatoes and up to 27.6% in total potato yield compared with the control.&lt;/p&gt;&lt;p&gt;The study</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</guid>
   <pubDate>Tue, 15 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Positive Third-Party Agrarius Potato Trial Results in Brazil</title>
   <link>http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</link>
   <description>
&lt;p&gt;&lt;b&gt;Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)-- The More Life Company Corp. (the “Company” or “TMLC”) (CSE: MLCO) (OTCID: TMLCF) is pleased to report positive results from an independently conducted field trial evaluating the Company’s licensed Agrarius™ agricultural plant signaling technology in potato crops in Brazil.&lt;/p&gt;&lt;p&gt;The leading Agrarius application programs recorded numerical yield increases of up to 32.5% in special-grade potatoes and up to 27.6% in total potato yield compared with the control.&lt;/p&gt;&lt;p&gt;The study</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</guid>
   <pubDate>Tue, 15 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
  <item>
   <title>The More Life Company Reports Positive Third-Party Agrarius Potato Trial Results in Brazil</title>
   <link>http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</link>
   <description>
&lt;p&gt;&lt;b&gt;Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs&lt;/b&gt;&lt;/p&gt;
&lt;p&gt;    TORONTO--(BUSINESS WIRE)-- The More Life Company Corp. (the “Company” or “TMLC”) (CSE: MLCO) (OTCID: TMLCF) is pleased to report positive results from an independently conducted field trial evaluating the Company’s licensed Agrarius™ agricultural plant signaling technology in potato crops in Brazil.&lt;/p&gt;&lt;p&gt;The leading Agrarius application programs recorded numerical yield increases of up to 32.5% in special-grade potatoes and up to 27.6% in total potato yield compared with the control.&lt;/p&gt;&lt;p&gt;The study</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/The+More+Life+Company+Reports+Positive+Third-Party+Agrarius+Potato+Trial+Results+in+Brazil/27061890.html</guid>
   <pubDate>Tue, 15 Sep 2026 08:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">MLCO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TMLCF</category>
   	  </item>
 </channel>
</rss>
